M. John Chapman

4.9k citations

49 papers · 3.4k indexed · h-index 28

Surgery top 2%
Endocrinology, Diabetes and Metabolism top 1%
Cancer Research top 2%
Molecular Biology top 10%
Cardiology and Cardiovascular Medicine top 5%

Co-authors: Anatol Kontush Laurent Camont W. Sean Davidson Marie Lhomme Sandrine Chantepie William R. Lagor P M Laplaud Mustapha Rouis
Topics: Lipoproteins and Cardiovascular Health (15 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers)Protease and Inhibitor Mechanisms (10 papers)
Cited by: Endocrinology, Diabetes and Metabolism Cancer Research Clinical Biochemistry
Journals: Proceedings of the National Academy of Sciences Circulation American Journal of Clinical Nutrition
Partner nations: France United States Australia

In The Last Decade

M. John Chapman

49 papers receiving 3.2k citations

Peers

Countries citing papers authored by M. John Chapman

Since Specialization

Citations

This map shows the geographic impact of M. John Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. John Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. John Chapman more than expected).

Fields of papers citing papers by M. John Chapman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. John Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. John Chapman. The network helps show where M. John Chapman may publish in the future.

Co-authorship network of co-authors of M. John Chapman

This figure shows the co-authorship network connecting the top 25 collaborators of M. John Chapman. A scholar is included among the top collaborators of M. John Chapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. John Chapman. M. John Chapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes 2018 ·Atherosclerosis ·Linda Liliana Muñóz-Hernández,(unknown),Griselda X. Brito-Córdova,(unknown),(unknown),Óscar Pérez‐Méndez,Alejandro Zentella‐Dehesa,(unknown),Marie Lhomme,Philippe Lesnik,M. John Chapman,Anatol Kontush,Carlos A. Aguilar‐Salinas	14
2	Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c Molecular and cell biology of lipids 2017 ·Biochimica et Biophysica Acta ·Leonardo Gómez Rosso,Marie Lhomme,Tomás Meroño,(unknown),Patricia Sorroche,Lyamine Hedjazi,(unknown),Vasily N. Sukhorukov,Alexander N. Orekhov,(unknown),M. John Chapman,Fernando Brites,Anatol Kontush	2
3	Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate 2017 ·Journal of Lipid Research ·L. Perségol,Maryam Darabi,(unknown),Marie Lhomme,Sandrine Chantepie,Kerry‐Anne Rye,Patrice Thérond,M. John Chapman,Robert Salvayre,Anne Nègre‐Salvayre,Philippe Lesnik,Serge Monier,Anatol Kontush	25
4	Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c 2016 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Leonardo Gómez Rosso,Marie Lhomme,Tomás Meroño,(unknown),Patricia Sorroche,Lyamine Hedjazi,(unknown),Vasily N. Sukhorukov,Alexander N. Orekhov,(unknown),M. John Chapman,Fernando Brites,Anatol Kontush	29
5	Structure of HDL: Particle Subclasses and Molecular Components 2014 ·Handbook of experimental pharmacology ·Anatol Kontush,Mats Lindahl,Marie Lhomme,Laura Calabresi,M. John Chapman,W. Sean Davidson	207
6	Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation 2014 ·Atherosclerosis ·Leonardo Gómez Rosso,Marie Lhomme,Tomás Meroño,Patricia Sorroche,Luís J. Catoggio,Enrique R. Soriano,(unknown),(unknown),(unknown),Laura Boero,Philippe Lesnik,Paul Robillard,M. John Chapman,Fernando Brites,Anatol Kontush	53
7	Distinct profiles of systemic biomarkers of oxidative stress in chronic human pathologies: Cardiovascular, psychiatric, neurodegenerative, rheumatic, infectious, neoplasmic and endocrinological diseases 2013 ·Advances in Bioscience and Biotechnology ·(unknown),(unknown),Y. Ménézo,(unknown),Gérard Dreyfus,M. John Chapman,Anatol Kontush	7
8	Blood Pressure-Lowering Response to Amlodipine as a Determinant of the Antioxidative Activity of Small, Dense HDL3 2011 ·American Journal of Cardiovascular Drugs ·Boris Hansel,Xavier Girerd,Dominique Bonnefont‐Rousselot,Randa Bittar,Sandrine Chantepie,Alexina Orsoni,Éric Bruckert,M. John Chapman,Anatol Kontush	4
9	Introduction 2010 ·Atherosclerosis Supplements ·M. John Chapman	5
10	Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl 2009 ·Archives of Biochemistry and Biophysics ·Sandrine Chantepie,Ernst Malle,Wolfgang Sattler,M. John Chapman,Anatol Kontush	17
11	A machine-learning approach to the prediction of oxidative stress in chronic inflammatory disease 2009 ·Redox Report ·(unknown),(unknown),Gérard Dreyfus,Yacine Oussar,Dominique Bonnefont‐Rousselot,M. John Chapman,Anatol Kontush	18
12	Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia 2007 ·American Journal of Clinical Nutrition ·Boris Hansel,Catherine Nicolle,Florent Lalanne,(unknown),Taous Lassel,Yves Donazzolo,Jean Ferrières,Michel Krempf,Jean‐Louis Schlienger,Bruno Vergès,M. John Chapman,Éric Bruckert	95
13	Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis 2007 ·Diabetologia ·Max Nieuwdorp,F. Holleman,Eric de Groot,Hans Vink,Johan Gort,Anatol Kontush,M. John Chapman,Barbara A. Hutten,Catherine B. Brouwer,J. B. L. Hoekstra,John J.P. Kastelein,Erik S.G. Stroes	79
14	Apolipoprotein E Knockout Mice Over-Expressing Human Tissue Inhibitor of Metalloproteinase 1 Are Protected against Aneurysm Formation but Not against Atherosclerotic Plaque Development 2006 ·Journal of Vascular Research ·(unknown),(unknown),Guilhem Larigauderie,(unknown),Christophe Furman,Martine Moreau,M. John Chapman,Jean‐Charles Fruchart,Mohamed Naceur Slimane,Hafid Mezdour,Mustapha Rouis	18
15	Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia 2005 ·Clinica Chimica Acta ·Mariame El Messal,Jean‐Louis Beaudeux,A. Drissi,Philippe Giral,(unknown),Éric Bruckert,A. Adlouni,M. John Chapman	26
16	Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives 2004 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Jean‐Louis Beaudeux,Philippe Giral,Éric Bruckert,Marie-José Foglietti,M. John Chapman	130
17	Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia 2003 ·Atherosclerosis ·Jean‐Louis Beaudeux,Philippe Giral,Éric Bruckert,(unknown),Marie-José Foglietti,M. John Chapman	83
18	Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux 2002 ·Atherosclerosis ·Maryse Guérin,(unknown),Céline Soudant,Wilfried Le Goff,Arie van Tol,(unknown),M. John Chapman	85
19	Plasma Lipoproteins in Preruminant Calves Fed Diets Containing Tallow or Soybean Oil with and Without Cholesterol 1996 ·Journal of Dairy Science ·(unknown),Dominique Bauchart,Denys Durand,P M Laplaud,M. John Chapman	28
20	Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase 1996 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·(unknown),Alexandros D. Tselepis,M. John Chapman,Ewa Ninio	69

About M. John Chapman

M. John Chapman is a scholar working on Endocrinology, Diabetes and Metabolism, Biochemistry and Cancer Research, having authored 49 papers that have together received 3.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (15 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Protease and Inhibitor Mechanisms (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.1k citations), Cancer Research (763 citations) and Clinical Biochemistry (262 citations). M. John Chapman has collaborated with scholars based in France, United States and Australia. Frequent co-authors include Anatol Kontush, Laurent Camont, W. Sean Davidson, Marie Lhomme, Sandrine Chantepie, William R. Lagor, P M Laplaud, Mustapha Rouis, Éric Bruckert and Dominique Hermier. Their work appears in journals such as Proceedings of the National Academy of Sciences, Circulation and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact